<DOC>
	<DOCNO>NCT02860650</DOCNO>
	<brief_summary>The purpose study test safety immunogenicity MVA-BN-Filo Ad26.Filo heterologous prime-boost vaccine regimens healthy adult participant .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Immunogenicity Heterologous Prime-boost Regimens Using Multivalent Filovirus Vaccines Ad26.Filo MVA-BN-Filo Administered Different Sequences Schedules Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Body mass index ( BMI ) great equal ( &gt; = ) 18.5 less ( &lt; ) 35.0 kilogram per square meter ( kg/m^2 ) Healthy basis physical examination , medical history , investigator 's clinical judgment All woman childbearing potential must negative serum ( betahuman chorionic gonadotropin [ betahCG ] ) pregnancy test screening , negative urine betahCG pregnancy test immediately prior study vaccine administration A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction start screen onwards least 3 month last vaccination Participant must available willing participate duration study visit followup Has vaccinate candidate filovirus vaccine Has receive Ad26 MVAbased candidate vaccine past Has diagnose disease cause Ebola virus ( EBOV ) , Marburg virus ( MARV ) , Sudan virus ( SUDV ) , Ta√Ø Forest virus ( TAFV ) expose EBOV , MARV , SUDV , TAFV , include participant travel epidemic filovirus area West Africa last 2 year ( , since start last Ebolavirus outbreak ) exclude study Chronic active hepatitis B hepatitis C infection , document hepatitis B surface antigen hepatitis C antibody , respectively Acute illness ( include minor illness diarrhea mild upper respiratory tract infection ) body temperature great equal ( &gt; = ) 38.0 degree Celsius Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>